20:33 , Oct 5, 2018 |  BC Week In Review  |  Company News

Janssen terminates licenses to Aduro cancer therapies

Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample, cell culture and mouse studies suggest inhibiting PCBP1 could help treat MS. In brain tissue samples from MS patients, PCBP1 expression was higher in MS lesions than in matched normal...
17:22 , Jul 27, 2018 |  BC Week In Review  |  Company News

Lee's mulls spin off, HK IPO for China oncology subsidiary

Lee's Pharmaceutical Holdings Ltd. (HKSE:950) said it will consolidate its oncology development pipeline into its China Oncology Focus Ltd. (COF) subsidiary. Lee's CFO Jason Chow told BioCentury that the company expects the reorganization to potentiate...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
18:13 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Replimune prices $100.5M IPO in middle of range

Replimune Group Inc. (NASDAQ:REPL) raised $100.5 million late July 19 through the sale of 6.7 million shares at $15 in an IPO underwritten by J.P. Morgan, Leerink and BMO Capital Markets. The price, which was...
02:48 , Jul 20, 2018 |  BC Extra  |  Financial News

Replimune ticks up after pricing $100.5M IPO

Replimune Group Inc. (NASDAQ:REPL) gained $0.16 to $15.16 on Friday after it raised $100.5 million through the sale of 6.7 million shares at $15 in an IPO. Underwriters are J.P. Morgan, Leerink and BMO Capital...
23:59 , Jun 21, 2018 |  BC Innovations  |  Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
19:24 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) raised $152.6 million on May 23 through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush. Kiniksa priced the...
15:31 , May 25, 2018 |  BC Week In Review  |  Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...